In situ assessment of beta-hexosaminidase activity
- PMID: 7495557
In situ assessment of beta-hexosaminidase activity
Abstract
We have adapted two methods to evaluate the beta-hexosaminidase (HEX) enzymatic activity in cultured cells, based on the use of (i) the fluorogenic substrate 4-methylumbelliferyl-6-sulfo-2-acetamido-2- deoxy-beta-D-glucopyranoside (MU-GlcNAc-6-SO4) and (ii) the naphthol AS-BI-N-acetyl-beta-D-glucosaminide and hexazotized pararosaniline. We demonstrate that both methods could be used for the HEX isoenzymes by comparing wild-type and mutant human fibroblast cell lines, deficient for either an alpha or beta subunit from Tay-Sachs and Sandhoff patients. This in situ cytochemical assessment of HEX activity offers a rapid evaluation to study the expression of this enzyme in a heterogeneous cell population such as in gene transfer experiments.
Similar articles
-
Isoenzymes of N-acetyl-beta-hexosaminidase.Acta Biochim Pol. 1999;46(3):739-51. Acta Biochim Pol. 1999. PMID: 10698282 Review.
-
Rapid detection of fetal Mendelian disorders: Tay-Sachs disease.Methods Mol Biol. 2008;444:147-59. doi: 10.1007/978-1-59745-066-9_11. Methods Mol Biol. 2008. PMID: 18425478
-
[Beta-N-acetyl-hexosaminidase--the enzyme of Tay-Sachs and Sandhoff diseases].Postepy Biochem. 1992;38(3):127-32. Postepy Biochem. 1992. PMID: 1461844 Review. Polish. No abstract available.
-
Restoration of hexosaminidase A activity in human Tay-Sachs fibroblasts via adenoviral vector-mediated gene transfer.Gene Ther. 1996 Sep;3(9):769-74. Gene Ther. 1996. PMID: 8875224
-
beta-hexosaminidase in cultured normal and mutant human fibroblasts: an immunohistochemical and biochemical investigation.Scand J Clin Lab Invest. 1991 Dec;51(8):711-4. doi: 10.3109/00365519109104585. Scand J Clin Lab Invest. 1991. PMID: 1839650
Cited by
-
Characterization of inducible models of Tay-Sachs and related disease.PLoS Genet. 2012 Sep;8(9):e1002943. doi: 10.1371/journal.pgen.1002943. Epub 2012 Sep 20. PLoS Genet. 2012. PMID: 23028353 Free PMC article.
-
Reversibility of neuropathology in Tay-Sachs-related diseases.Hum Mol Genet. 2014 Feb 1;23(3):730-48. doi: 10.1093/hmg/ddt459. Epub 2013 Sep 20. Hum Mol Genet. 2014. PMID: 24057669 Free PMC article.
-
AAV-mediated gene delivery in a feline model of Sandhoff disease corrects lysosomal storage in the central nervous system.ASN Neuro. 2015 Apr 13;7(2):1759091415569908. doi: 10.1177/1759091415569908. Print 2015 Mar-Apr. ASN Neuro. 2015. PMID: 25873306 Free PMC article.
-
Widespread correction of central nervous system disease after intracranial gene therapy in a feline model of Sandhoff disease.Gene Ther. 2015 Feb;22(2):181-9. doi: 10.1038/gt.2014.108. Epub 2014 Dec 4. Gene Ther. 2015. PMID: 25474439
-
Therapeutic benefit after intracranial gene therapy delivered during the symptomatic stage in a feline model of Sandhoff disease.Gene Ther. 2021 Apr;28(3-4):142-154. doi: 10.1038/s41434-020-00190-1. Epub 2020 Sep 3. Gene Ther. 2021. PMID: 32884151 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials